Cross-Reactive Bactericidal Antimeningococcal Antibodies Can Be Isolated From Convalescing Invasive Meningococcal Disease Patients Using Reverse Vaccinology 2.0
The threat from invasive meningococcal disease (IMD) remains a serious source of concern despite the licensure and availability of vaccines. A limitation of current serogroup B vaccines is the breadth of coverage afforded, resulting from the capacity for extensive variation of the meningococcus and...
Main Authors: | Fadil A. Bidmos, Simon Nadel, Gavin R. Screaton, J. Simon Kroll, Paul R. Langford |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-07-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2018.01621/full |
Similar Items
-
Cross-reactive bactericidal antimeningococcal antibodies can be isolated from convalescing invasive meningococcal disease patients using reverse vaccinology 2.0
by: Bidmos, F, et al.
Published: (2018) -
Meningococcal vaccines: past, present, and future perspectives
by: Seyed Davar Siadat and Dariush Norouzian
Published: (2007-10-01) -
Vaccines against Meningococcal Diseases
by: Mariagrazia Pizza, et al.
Published: (2020-10-01) -
MENINGOCOCCAL SEPSIS – CASE REPORT
by: Andreja Cokan, et al.
Published: (2002-01-01) -
On the controversy about the efficacy of the antimeningococcal B vaccine: methodological pitfalls
by: Eduardo de A. Costa